Find a Physician | How to Contribute | About Us | Clinical Trials
 
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Skin

The BAMM Trial: BRAF, Autophagy and MEK inhibition in Metastatic Melanoma: A Phase 1/2 Open Label Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Patients with Advanced BRAF Mutant Melanoma

The purpose of this study is to: • Determine the maximum tolerated dose of hydroxychloroquine which can be safely combined with dabrafenib and trametinib • Determine how effective this three drug combination is in shrinking tumors and • Perform laboratory based tests to assist in understanding how these drugs work in patients with advanced melanoma

Status: Accepting New Patients
Principal Investigator: Sunandana Chandra

A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects With Advanced Malignancies

To find out if the study drug INCB059872 is safe and may have beneficial effects in people who have different types of cancer.

Status: Accepting New Patients
Principal Investigator: Young Chae

A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

The purpose of this study is to evaluate the safety, as assessed by incidence of DLT, of talimogene laherparepvec in combination with pembrolizumab in subjects w/ previously untreated, unresectable, stage IIIB to IVM1c melanoma.

Status: Accepting New Patients
Principal Investigator: Sunandana Chandra

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

The purpose of this study is to test any good and bad effects of the combination of study drugs called ipilimumab and nivolumab in treating rare cancers and cancers of unknown primary origin.

Status: Accepting New Patients
Principal Investigator: Young Chae

A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

The purpose of this research study is to compare the good and bad effects of the sequence of immunotherapy (combination of ipilimumab and nivolumab) followed by BRAF inhibitor therapy (combination of dabrafenib and trametinib) if and when the disease becomes resistant, to the sequence of BRAF inhibitor therapy (combination of dabrafenib and trametinib) followed by immunotherapy (combination of ipilimumab and nivolumab) if and when the disease becomes resistant.

Status: Accepting New Patients
Principal Investigator: Sunandana Chandra

An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-659 in Adult Patients with Advanced Solid Tumor and Lymphoma Malignancies

Two of the main purposes of this study are to determine the side effects and risks of TAK-659 and the highest dose of TAK-659 that can be given to patients daily without causing side effects and risks that are too severe.

Status: Accepting New Patients
Principal Investigator: Jason Kaplan

Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy with Or without Hippocampal Avoidance In Patients with Brain Metastases

To determine whether minimizing radiation dose to the hippocampus (a brain structure that is important for memory) during whole-brain radiation can decrease the risk of cognitive side effects after radiation therapy to the brain to using the usual whole-brain radiation plus memantine (a drug that can also reduce cognitive side effects of brain radiation).

Status: Accepting New Patients
Principal Investigator: Timothy Kruser

A Prospective, Randomized, Blinded, Placebocontrolled, Phase IIb Trial of an Autologous Tumor Lysate (Tl) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine vs Unloaded YCWP + DC In Stage III and Stage IV (Resected) Melanoma to Prevent Recurrence

The purpose of this study is to (1) produce and test a vaccine that is made from your tumor cells and white blood cells to determine if it can prevent melanoma recurrence; (2) to look at the safety of the vaccine (what side effects it has); and (3) to look at the immune system’s response to this vaccine.

Status: Accepting New Patients
Principal Investigator: Sunandana Chandra

A Randomized Open-Label Pilot Trial to Evaluate the Safety and Efficacy of Repetitive Transcranial Magnetic Stimulation in Cancer Patients with Depression and Anxiety

The purpose of this study is to test the safety and tolerability of left- and right-sided rTMS as a treatment for depression in the cancer population.

Status: Accepting New Patients
Principal Investigator: Mehmet Dokucu

Extended Duration Varenicline for Smoking among Cancer Patients: A Clinical Trial

The main purpose of this research study is to compare 12 versus 24 weeks of varenicline treatment, also known as Chantix®, for smoking cessation.

Status: Accepting New Patients
Principal Investigator: Brian Hitsman

last updated: Thu - October 19, 2017 - 07:10 AM

Fetching Clinical Trial!

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.